1 Corporate Presentation June 2020 Forward Looking Statement This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and a ...

Confidential Corporate Presentation May 2020 Forward Looking Statement This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of cur ...

Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2020 Earnings Conference Call May 12, 2020 4:30 PM ET Company Participants Bryan Giraudo - Chief Financial Officer Sheila Gujrathi - Co-founder & Chief Executive Officer Luisa Salter-Cid - Chief Scientific Officer Richard Aranda - Senior Vice President Conference Call Participants Joseph Schwartz - SVB Leerink Eliana Merle - Cantor Fitzgerald Carter Gould - Barclays Tyler Van Buren - Piper Sandler David Hoang - SMBC Operator Ladies and gentlemen, thank you for standing by ...

Gossamer Bio, Inc. (NASDAQ:GOSS) Q3 2019 Earnings Conference Call November 12, 2019 4:30 PM ET Company Participants Bryan Giraudo - Chief Financial Officer Sheila Gujrathi - Co-founder & Chief Executive Officer Jakob Dupont - Chief Medical Officer Luisa Salter-Cid - Chief Scientific Officer Conference Call Participants Joseph Schwartz - SVB Leerink Operator Good afternoon, and welcome to the Gossamer Bio Third Quarter 2019 Earnings Call. Today's call will feature updates from Gossamer Bio's management team ...

Confidential Corporate Presentation Forward Looking Statement This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and ...

Gossamer Bio, Inc. (NASDAQ:GOSS) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET Company Participants Bryan Giraudo - CFO Sheila Gujrathi - Co-Founder, President, CEO & Director Jakob Dupont - Chief Medical Officer Conference Call Participants Joseph Schwartz - SVB Leerink Operator Good day, ladies and gentlemen, and welcome to the Gossamer Bio Second Quarter 2019 Earnings Conference Call. [Operator Instructions]. As a reminder, this conference is being recorded. I'd now like to turn the conferen ...

Confidential Corporate Presentation Forward Looking Statement This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and ...

Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2019 Results Earnings Conference Call May 14, 2019 8:30 AM ET Company Participants Bryan Giraudo - CFO Sheila Gujrathi - Co-Founder and CEO Conference Call Participants Ying Huang - Bank of America/Merrill Lynch Joseph Schwartz - SVB Leerink Josh Schimmer - Evercore Operator Good morning, and welcome to the Gossamer Bio First Quarter 2019 Earnings Call. Today's call will feature updates from Gossamer Bio management's team followed by a question-and-answer session. I would ...